{
    "clinical_study": {
        "@rank": "109167", 
        "arm_group": [
            {
                "arm_group_label": "patients", 
                "arm_group_type": "Experimental", 
                "description": "patients allergic to house dust mite receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit"
            }, 
            {
                "arm_group_label": "healthy controls", 
                "arm_group_type": "Sham Comparator", 
                "description": "healthy controls receive sham solution for 5 minutes on first visit and histamine (16mg/ml) for 5 minutes on second visit"
            }
        ], 
        "brief_summary": {
            "textblock": "In order to evaluate the effects a nasal provocation on the activation of different brain\n      regions, the investigators want to set up a clinical trial investigating the short-term\n      effects of a nasal histamine provocation in healthy volunteers and allergic patients while\n      in supine position under the functional MRI device in order to visualize different brain\n      regions."
        }, 
        "brief_title": "Role of the Central Nervous System in Allergic Rhinitis", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "House Dust Mite Allergy", 
        "condition_browse": {
            "mesh_term": "Rhinitis"
        }, 
        "detailed_description": {
            "textblock": "Evaluate the effects a nasal provocation on the activation of different brain regions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a positive skin prick test to grass pollen and with pollen allergic\n             symptoms during the pollen season OR patients with a negative skin prick test and\n             with no allergic symptoms during the pollen season.\n\n          -  Age > 18 and < 50 years\n\n          -  Written informed consent\n\n          -  Willingness to adhere to visit schedules\n\n          -  Adequate contraceptive precautions in female patients with childbearing potential\n\n        Exclusion Criteria:\n\n          -  Current or recent (finished less than 2 years) immunotherapy against grass pollen.\n\n          -  Systemic steroid treatment less than 6 weeks before the inclusion in the study.\n\n          -  Nasal steroid spray, oral leukotriene antagonists or long-acting antihistamines less\n             than 4 weeks before the inclusion.\n\n          -  Presence of purulent secretions in nasal cavity.\n\n          -  Severe septal deviation (septum reaching concha inferior or lateral nasal wall).\n\n          -  Patient is pregnant or breastfeeding.\n\n          -  Patient has any disorder of which the investigators feel at the time of evaluation\n             for participation in the study that this may compromise the ability to give truly\n             informed consent for participation in this study.\n\n          -  Patient is currently enrolled in other investigational drug  trial(s) or is receiving\n             other investigational agent(s) for any other medical condition.\n\n          -  No independent medication management in daily life or disability to perform fine\n             motoric handling of medication\n\n          -  Patients with asthma will be excluded.\n\n          -  Patients suffering from claustrophobia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01777464", 
            "org_study_id": "september2012"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "patients", 
                    "healthy controls"
                ], 
                "description": "administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan", 
                "intervention_name": "histamine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "patients", 
                    "healthy controls"
                ], 
                "description": "sham solution", 
                "intervention_name": "sham", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Histamine", 
                "Histamine phosphate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leuven", 
                    "country": "Belgium", 
                    "state": "Vlaams Brabant", 
                    "zip": "3000"
                }, 
                "name": "uz leuven ORL"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_arms": "2", 
        "official_title": "Role of the Central Nervous System in Allergic Rhinitis: Activation of Different Brain Regions After a Nasal Histamine Provocation in Healthy and Allergic Patients", 
        "overall_official": {
            "affiliation": "KU Leuven", 
            "last_name": "Peter Hellings, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The specific aim of this study is to visualize the type and location of brain activation in healthy and allergic volunteers by a nasal provocation with histamine, using the functional MRI technology.", 
            "measure": "brain activation", 
            "safety_issue": "No", 
            "time_frame": "5 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01777464"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation of nasal symptoms (runny nose, blocked nose, itchy nose and post-nasal drip) and conjunctival symptoms (lacrimation and itchy eyes) will be done with VAS scores and the Peak Nasal Inspiratory Flow (PNIF) will be measured before and after both fMRI scans", 
            "measure": "nasal symptoms and Peak Nasal Inspiratory Flow", 
            "safety_issue": "No", 
            "time_frame": "before and after scans"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}